Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Conmed, Lowers Price Target to $123

Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $127 to $123.

byBenzinga Newsdesk

August 2, 2022

1 minute read

Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $127 to $123.

This Small Biotech Company Touts Promising Data For Alzheimer’s Candidate

By Vandana Singh

Today, 6:04 AM

BioVie Inc (NASDAQ:BIVI) announced topline results from an investigator-Sponsored Phase 2 trial of NE3107 for Alzheimer’s Disease (AD). The company says…

BIVI

Baird Upgrades Fluor to Outperform, Lowers Price Target to $29

By Benzinga Newsdesk

Today, 6:04 AM

Baird analyst Andrew Wittmann upgrades Fluor (NYSE:FLR) from Neutral to Outperform and lowers the price target from $30 to $29.

FLR

Jowell Global Q1 Sales $28.40M Up From $9.50M YoY

By Benzinga Newsdesk

Today, 6:04 AM

Jowell Global (NASDAQ:JWEL) reported $28.40 million in sales this quarter. This is a 198.95 percent increase over sales of $9.50 million the same period last year.

JWEL